Description
Adolescent Type 1 diabetes Treatment with EMPaglifozin for hyperglycemia & hyperfilTration Trial, "ATTEMPT" Trial
Amendment chain · 1 entry
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header.
- #02018-04-01$843,990
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2018-04-01(start date) | $843,990 | — | Adolescent Type 1 diabetes Treatment with EMPaglifozin for hyperglycemia & hyperfilTration Trial, "ATTEMPT" Tr… |
Related records · 2
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (exact legal name match; no business number on file)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 236-2022-2023-Q4-00715 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada · Research in Priority Areas Research in Priority Areas | $1,546,845 | FY2023 |
| 236-2021-2022-Q1-00670 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada · Research in Priority Areas | $9,974 | FY2022 |
Cite as: Glassbox record view · Federal grants & contributions · 236-2018-2019-Q1-00380 · retrieved 2026-11-15.